Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHZ5SB)

• Drug Name: 8-Methoxy-quinolin-2-ylamine Drug Info
• Synonyms: 2-Quinolinamine, 8-methoxy-; 8-Methoxyquinolin-2-amine; 104090-86-0; CHEMBL77072; 8-Methoxy-quinolin-2-ylamine; ACMC-20m6vk; SCHEMBL1655715; CTK0G6598; DTXSID90624077; MolPort-020-915-686; PMXFKGCLUAFLMH-UHFFFAOYSA-N; 2-AMINO-8-METHOXYQUINOLINE; ZINC26399714; BDBM50025466; AKOS013465271

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 22266820
  CAS Number: CAS 104090-86-0
  TTD Drug ID: DMHZ5SB

Molecule-Related Drug Atlas

Drug(s) Targeting Melanin-concentrating hormone receptor 1 (MCHR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-830216	DMCW71N	Obesity	5B81	Phase 1	[3]
AZD1979	DMQ1OX4	Obesity	5B81	Phase 1	[4]
PMID25522065-Compound-27	DMXN4KB	N. A.	N. A.	Patented	[5]
PMID25522065-Compound-29	DMBNAK9	N. A.	N. A.	Patented	[5]
PMID25522065-Compound-34	DMZDIRQ	N. A.	N. A.	Patented	[5]
PMID25522065-Compound-39	DM5YMQH	N. A.	N. A.	Patented	[5]
PMID25522065-Compound-40	DMCIQ01	N. A.	N. A.	Patented	[5]
PMID25522065-Compound-11	DM410Z6	N. A.	N. A.	Patented	[5]
PMID25522065-Compound-50	DMBWA0V	N. A.	N. A.	Patented	[5]
PMID25522065-Compound-12	DMVKO9C	N. A.	N. A.	Patented	[5]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[6]
Eletriptan	DMW649X	Migraine	8A80	Approved	[7]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[7]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[7]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[8]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[9]
Almogran	DM7I64Z	Migraine	8A80	Approved	[10]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[11]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[12]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[13]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[7]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[14]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[15]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[16]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[17]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[18]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[19]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[20]
Treximet	DMU54QB	Migraine	8A80	Approved	[21]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Inhibitor	[1]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Inhibitor	[1]
Melanin-concentrating hormone receptor 1 (MCHR1)	TTX4RTB	MCHR1_HUMAN	Inhibitor	[2]

References

• [1] 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
• [2] Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7.
• [3] 2011 Pipeline of Bristol-Myers Squibb.
• [4] Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
• [5] Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
• [6] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [9] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [10] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [11] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Company report (NeurAxon)
• [14] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [15] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [16] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [17] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [18] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [19] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [20] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [21] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)